Impact of Humira Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice -HOPE
Phase of Trial: Phase IV
Latest Information Update: 30 May 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Intermediate uveitis; Panuveitis; Posterior uveitis
- Focus Therapeutic Use
- Acronyms HOPE
- Sponsors AbbVie
- 22 May 2018 Planned End Date changed from 2 May 2019 to 31 Dec 2019.
- 22 May 2018 Planned primary completion date changed from 2 May 2019 to 31 Dec 2019.
- 16 Nov 2017 Planned End Date changed from 20 Jun 2019 to 2 May 2019.